Burrows Scott Linsider trades
In SEC Form 4 filings, Burrows Scott L is listed as Chief Financial Officer of Spyre Therapeutics, Inc. (SYRE). In the last 90 days, Burrows Scott L sold $4.55M of Spyre Therapeutics, Inc. (SYRE) on the open market and bought none. All 11 sales were reported under a 10b5-1 trading plan.
Companies and roles
| Company | Role | Transactions | Last filed |
|---|---|---|---|
| SYRESpyre Therapeutics, Inc. | Chief Financial Officer | 17 | Oct 2 |
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-09-03
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| SYRESpyre Therapeutics, Inc. | Oct 1 | Oct 2 | M | 7,500 | $14.50 | $108,750 | 87,262 | Yes | Form 4 |
| SYRESpyre Therapeutics, Inc. | Oct 1 | Oct 2 | S | 600 | $89.07 | Sale −$53,442 | 86,662 | Yes | Form 4 |
| SYRESpyre Therapeutics, Inc. | Oct 1 | Oct 2 | S | 1,500 | $90.27 | Sale −$135,405 | 85,162 | Yes | Form 4 |
| SYRESpyre Therapeutics, Inc. | Oct 1 | Oct 2 | S | 2,100 | $91.92 | Sale −$193,032 | 83,062 | Yes | Form 4 |
| SYRESpyre Therapeutics, Inc. | Oct 1 | Oct 2 | S | 3,071 | $92.95 | Sale −$285,449 | 79,991 | Yes | Form 4 |
| SYRESpyre Therapeutics, Inc. | Oct 1 | Oct 2 | S | 229 | $93.57 | Sale −$21,428 | 79,762 | Yes | Form 4 |
| SYRESpyre Therapeutics, Inc. | Oct 1 | Oct 2 | M · derivative | 7,500 | $14.50 | $108,750 | 312,357 | Yes | Form 4 |
| SYRESpyre Therapeutics, Inc. | Sep 30 | Oct 2 | M | 17,500 | $14.50 | $253,750 | 97,262 | Yes | Form 4 |
| SYRESpyre Therapeutics, Inc. | Sep 30 | Oct 2 | S | 17,500 | $89.89 | Sale −$1,573,075 | 79,762 | Yes | Form 4 |
| SYRESpyre Therapeutics, Inc. | Sep 30 | Oct 2 | M · derivative | 17,500 | $14.50 | $253,750 | 319,857 | Yes | Form 4 |
| SYRESpyre Therapeutics, Inc. | Sep 2 | Sep 3 | S | 18,232 | $89.35 | Sale −$1,629,029 | 79,762 | Yes | Form 4 |
| SYRESpyre Therapeutics, Inc. | Sep 1 | Sep 3 | M | 7,500 | $14.50 | $108,750 | 105,494 | Yes | Form 4 |
| SYRESpyre Therapeutics, Inc. | Sep 1 | Sep 3 | S | 900 | $86.25 | Sale −$77,625 | 104,594 | Yes | Form 4 |
| SYRESpyre Therapeutics, Inc. | Sep 1 | Sep 3 | S | 4,384 | $87.11 | Sale −$381,890 | 100,210 | Yes | Form 4 |
| SYRESpyre Therapeutics, Inc. | Sep 1 | Sep 3 | S | 2,016 | $88.03 | Sale −$177,468 | 98,194 | Yes | Form 4 |
| SYRESpyre Therapeutics, Inc. | Sep 1 | Sep 3 | S | 200 | $89.04 | Sale −$17,808 | 97,994 | Yes | Form 4 |
| SYRESpyre Therapeutics, Inc. | Sep 1 | Sep 3 | M · derivative | 7,500 | $14.50 | $108,750 | 337,357 | Yes | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.